Advanced Radiotherapy (ART) in Prostate Cancer (PROST-ART)
Launched by IRCCS SAN RAFFAELE · Aug 6, 2024
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
The PROST-ART clinical trial is looking at how effective advanced types of radiotherapy, such as Image-Guided Radiotherapy (IGRT), Intensity-Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT), and PET-guided treatments, are for men with different stages of prostate cancer. This study reviews the experiences of patients treated at a specific hospital from 2004 to 2024. It aims to understand how these treatments work for patients with low to very high-risk prostate cancer or those who have had a recurrence of cancer.
To participate in this study, you need to be a man over 18 years old with prostate cancer who has received one of the advanced radiotherapy treatments mentioned. However, if you have other types of cancer or are over 95 years old, you would not be eligible. If you join this trial, you can expect to contribute to important research that may help improve treatment options for prostate cancer in the future. The study is currently recruiting participants, and your involvement could make a difference for many others facing this disease.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Prostate cancer patients, \> 18 years old, treated with IGRT, IMRT, SBRT
- Exclusion Criteria:
- • other tumors
- • \> 95 years old
About Irccs San Raffaele
IRCCS San Raffaele is a prestigious research hospital and clinical trial sponsor based in Milan, Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As an Institute for Research and Healthcare, it specializes in a wide range of therapeutic areas, including oncology, neurology, and cardiology, and is dedicated to translating scientific discoveries into effective clinical practices. With a multidisciplinary team of experts and state-of-the-art facilities, IRCCS San Raffaele plays a pivotal role in conducting rigorous clinical trials that contribute to the development of novel treatments and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, , Italy
Patients applied
Trial Officials
Nadia G Di Muzio, Prof
Principal Investigator
IRCCS San Raffaele, Milan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported